145 / 172
145
radiographic outcomes of four different treatment strategies in
patients with early rheumatoid arthritis (the BeSt study): a
randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
27. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB,
Pavelka K, van Vollenhoven R, et al. The PREMIER study: a
multicenter, randomized, double-blind clinical trial of
combination therapy with adalimumab plus methotrexate
versus methotrexate alone or adalimumab alone in patients
with early, aggressive rheumatoid arthritis who had not had
previous methotrexate treatment. Arthritis Rheum 2006;54:26-
37.
28. Emery P, Genovese MC, van Vollenhoven R, Sharp JT,
Patra K, Sasso EH. Less radiographic progression with
adalimumab plus
methotrexate
versus
methotrexate
monotherapy across the spectrum of clinical response in early
rheumatoid arthritis. J Rheumatol 2009;36:1429-41.
29. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon
JM, Keystone E, et al. Radiographic changes in rheumatoid
arthritis patients attaining different disease activity states with
methotrexate monotherapy and infliximab plus methotrexate:
the impacts of remission and tumour necrosis factor blockade.
Ann Rheum Dis 2009;68:823-7.
30. Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van
Vollenhoven R, et al. Rapid and sustained improvements in
health-related quality of life, fatigue, and other patient-
reported outcomes in rheumatoid arthritis patients treated
with certolizumab pegol plus methotrexate over 1 year: results
from the RAPID 1 randomized controlled trial. Arthritis Res
Ther 2009;11:R170.
31. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D,
Luijtens K, et al. Efficacy and safety of certolizumab pegol plus
methotrexate in active rheumatoid arthritis: the RAPID 2
study. A randomised controlled trial. Ann Rheum Dis
2009;68:797-804.